Dr. Carsten Brockmeyer studied biology at the University of Göttingen and received a doctoral degree in human biology from Hanover Medical School. He then worked as postdoctoral fellow for two years at the Institute of Immunology, Ludwig Maximilian University of Munich. He began his industrial career as scientific group leader at Baxter Deutschland GmbH, Biotech Division, where he later became science director, responsible for development and quality control of monoclonal antibodies and novel cell therapy products.
In 1998 Dr. Brockmeyer took a position as project manager biotechnology at Hexal AG, where he was then appointed in 1999 to general manager of HEXAL Biotech Forschungs GmbH, overseeing the development, manufacturing and quality control of the first-ever biosimilar for epoetin alfa and for a biosimilar filgrastim. Afterwards Dr. Brockmeyer became head of global project management at Sandoz Biopharmaceuticals, where he continued to direct the development of important biosimilars at Hexal/Sandoz. Before joining Formycon AG as CEO in April 2013, Dr. Brockmeyer founded Brockmeyer Biopharma GmbH in 2010, and helped to establish the biosimilar programs at Formycon AG since 2012.
Dr. Brockmeyer is the author of more than 100 scientific publications and credited with a number of patented inventions. His acclaimed work in the field of biopharmaceuticals has been recognized with prestigious scientific awards. Dr. Brockmeyer has been ranked repeatedly among the most influential people across the globe in the field of medicine by the journal “The Medicine Maker”.